# RELVAR® 100 ELLIPTA® Special Drug Use Investigation (COPD, Long-term)

> **NCT03219255** · — · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 1047 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** RELVAR 100 ELLIPTA

## Key facts

- **NCT ID:** NCT03219255
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-30
- **Primary completion:** 2021-03-30
- **Final completion:** 2021-03-30
- **Target enrollment:** 1047 (ACTUAL)
- **Last updated:** 2021-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03219255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03219255, "RELVAR® 100 ELLIPTA® Special Drug Use Investigation (COPD, Long-term)". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03219255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*